Press Releases

Accuray to Showcase New CyberKnife® and TomoTherapy® Technologies at ESTRO 2015

Sunnyvale, Calif., April 23, 2015 – Accuray Incorporated (Nasdaq: ARAY) announced today that the company will highlight new CyberKnife® and TomoTherapy® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. The CyberKnife and TomoTherapy Systems are used to treat cancerous and benign tumors throughout the body. Each system precisely targets the tumor, delivering the prescribed radiation dose, while minimizing exposure to nearby healthy organs and tissues. At ESTRO, Accuray will showcase:

Read More »
Accuray Establishes First TomoTherapy® and CyberKnife® System Education Centers in China SUNNYVALE, Calif., April 13, 2015 – Accuray Incorporated (Nasdaq: ARAY) announced today that they have collaborated with leading cancer hospitals to establish professional radiotherapy education centers in China. The goal of these centers is to use clinical training and continuing education to provide practitioners with education on the use of radiation to treat cancerous tumors. With the rapid development of cancer treatment techniques, radiotherapeutic equipment upgrades and adoption of new radiotherapy technologies, there is an opportunity to provide practitioners with additional information on the role of radiation therapy in cancer management. Read More »
Accuray To Report Results For Third Quarter Fiscal 2015 On April 30, 2015 SUNNYVALE, Calif., April 9, 2015 -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2015 on April 30, 2015 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day. Read More »
Accuray and Christie InnoMed Sign Exclusive Sales Agent Agreements for Radiation Therapy Systems in Canada SUNNYVALE, Calif., March 5, 2015 -- Accuray Incorporated (Nasdaq: ARAY) and Christie InnoMed Inc. announced today that they have entered into sales agent agreements involving the CyberKnife® and TomoTherapy® System product portfolios in Canada. Under the terms of these agreements, Christie InnoMed will be the exclusive sales agent for Accuray products in this region. Read More »
First Patient Treatment with the CyberKnife® M6™ System and the InCise™ Multileaf Collimator Has Been Completed SUNNYVALE, Calif., March 2, 2015 -- Accuray Incorporated (Nasdaq: ARAY) announced today that the first patient treatment has been completed using the CyberKnife® M6™ System with the InCise™ Multileaf Collimator (MLC). The treatment was administered as a multidisciplinary effort between Dr. Steven Burton from the Department of Radiation Oncology and Dr. Johnathan Engh from the Department of Neurosurgery at UPMC in Pittsburgh, Pennsylvania. UPMC was one of the InCise MLC evaluation sites working in collaboration with Accuray. Read More »
Erste Patientenbehandlung mit dem CyberKnife® M6™-System und dem InCise™ Multileaf-Kollimator ist abgeschlossen SUNNYVALE, Kalifornien, 2. März 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) meldete heute die erste unter Einsatz des CyberKnife® M6™-Systems mit dem InCise™ Multileaf-Kollimator (MLC) abgeschlossene Patientenbehandlung. Die Behandlung wurde multidisziplinär durch Dr. Steven Burton von der Abteilung für Radioonkologie und Dr. Johnathan Engh von der Abteilung für Neurochirurgie am UPMC in Pittsburgh (Pennsylvania) durchgeführt. Das UPMC war in Kooperation mit Accuracy eines der Evaluierungszentren für InCise MLC. Read More »
Le premier traitement d'un patient avec le système CyberKnife® M6™ et le collimateur multilames InCise™ a été mené à terme

SUNNYVALE, Californie, 2 mars 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq : ARAY) a annoncé aujourd'hui que le premier traitement d'un patient a été mené à terme à l'aide du système CyberKnife® M6™ couplé au collimateur multilames (MLC) InCise™. L'administration du traitement reflète les efforts multidisciplinaires du Dr Steven Burton du département de radio-oncologie et du Dr Johnathan Engh du département de neurochirurgie de l'UPMC de Pittsburgh, Pennsylvanie.

Read More »

Pages